China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints
This article was originally published in The Pink Sheet Daily
Firm aims to partner for Phase III development of HMPL-004, particularly in the U.S. and Europe. "We are flexible in terms of partnerships, whether they are co-development or co-promotional in nature," CEO says..
You may also be interested in...
With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner
BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner
BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer
China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen
BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives